Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy
2024

Case Report on Denosumab Triggering Osteonecrosis in Osteoporosis Patient

Sample size: 1 publication Evidence: low

Author Information

Author(s): Száraz Dávid, Peřina Vojtěch, Treglerová Jana, Macháček Ctirad, Zendulka Ondřej, Bořilová Linhartová Petra

Primary Institution: University Hospital Brno, Czechia

Hypothesis

Can a single low dose of denosumab trigger medication-related osteonecrosis of the jaw (MRONJ) in patients previously treated with bisphosphonates?

Conclusion

A single low dose of denosumab can trigger MRONJ in patients with a history of bisphosphonate therapy.

Supporting Evidence

  • Only six similar cases of MRONJ after a single low dose of denosumab have been reported.
  • The patient developed MRONJ stage III three months after receiving denosumab.
  • Previous treatment with bisphosphonates may have contributed to the rapid onset of MRONJ.

Takeaway

This study shows that even one shot of a medicine called denosumab can cause serious jaw problems in older people who have taken other medicines for bone health.

Methodology

Case report and literature review.

Potential Biases

Potential bias due to the retrospective nature of the literature review.

Limitations

The findings are based on a single case and may not be generalizable.

Participant Demographics

An 83-year-old female patient with osteoporosis and multiple comorbidities.

Digital Object Identifier (DOI)

10.3389/froh.2024.1473049

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication